NSE ScannerHospitals & Diagnostics · Hospital/Nursing Management · NSE: GKSL · data 2026-10-31
Gujarat Kidney & Super Speciality Ltd.
In plain words
Price: 22.2% below its 52-week high of ₹209.8.
Delivery: 55.0% of traded shares were kept for delivery over the last 10 sessions, against 41.7% over the last 60.
Latest results: a net profit of ₹5 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹101 cr |
| Net profit (last 12 months) | ₹16 cr |
| Sales growth, 3 years (yearly) | — |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 71.5%, pledged 0.0%, institutions 6.8%.
P/E 81.3, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 11.1%, ROCE 14.7%, operating margin 21.3%: how much profit it earns on the money it uses.
Debt/equity 0.12, Profit growth — and sales growth — a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Healthy operating margin (21.3%).
- Expensive on earnings (P/E 81.3).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
GKSL Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹34.29 crore, up 12.1% QoQ.
Net profit was ₹5.18 crore, up 2.8% QoQ.
Operating margin was 24.4%.
EPS was ₹0.66, up 3.1% QoQ.
GKSL के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹34.29 करोड़; पिछली तिमाही की तुलना में 12.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹5.18 करोड़; पिछली तिमाही की तुलना में 2.8% की बढ़त।
ऑपरेटिंग मार्जिन: 24.4%।
EPS: ₹0.66; पिछली तिमाही की तुलना में 3.1% की बढ़त।
GKSLના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹34.29 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 12.1% વધારો.
ચોખ્ખો નફો: ₹5.18 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 2.8% વધારો.
ઓપરેટિંગ માર્જિન: 24.4%.
EPS: ₹0.66; ગયા ક્વાર્ટરની સરખામણીએ 3.1% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 13.4% over the last 20 sessions vs 37.6% in the 40 before (0.36x); shares delivered per day 1.21x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹15.01 cr in bulk/block deals over 90 days (0 net buying days, 3 net selling days): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 26 Oct 26Deal Bulk deal: NEXUS GLOBAL OPPORTUNITIES FUND sold ₹7.81 cr -1.2% next session
- 1 Oct 26Deal Bulk deal: NATVARSINH T CHAVDA sold ₹2.42 cr (net −₹1.52 cr) +6.3% next session
- 22 Sept 26Deal Bulk deal: L7 HITECH PRIVATE LIMITED sold ₹5.68 cr -3.0% next session
- 5 Aug 26Results Q2 FY26 results: net profit ₹2.7 cr +2.6% next session
- 25 Jul 26Results Q4 FY26 results: net profit ₹5 cr -0.6% next session
- 2 May 26Results Q3 FY26 results: net profit ₹2.9 cr +0.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹34 cr | ₹5 cr | — | 24.4% | 0.66 |
| Mar 2026 | ₹31 cr | ₹5 cr | — | 20.6% | 0.81 |
| Dec 2025 | ₹23 cr | ₹3 cr | — | 29.7% | 0.52 |
| Sept 2025 | ₹13 cr | ₹3 cr | — | 39.6% | 0.52 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 71.45% | 71.45% | 71.45% | 71.45% |
| Foreign institutions (FII) | 6.53% | 4.88% | 4.88% | 10.47% |
| Domestic institutions (DII) | 0.26% | 0.56% | 0.56% | 1.67% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 5.08% | 5.74% | 5.74% | 9.08% |
| Number of shareholders | 12,986 | 18,301 | 18,301 | 27,783 |
Common questions
What was Gujarat Kidney & Super Speciality Ltd.'s latest quarterly profit?
Gujarat Kidney & Super Speciality Ltd. reported a net profit of ₹5 cr for the quarter ended Jun 2026, on revenue of ₹34 cr.
How much do promoters hold in Gujarat Kidney & Super Speciality Ltd.?
Promoters held 71.45% of Gujarat Kidney & Super Speciality Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Gujarat Kidney & Super Speciality Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.12.
What is Gujarat Kidney & Super Speciality Ltd.'s P/E ratio?
About 81.3, based on the last 12 months' earnings and a price of ₹163.31 (data 2026-10-31).
What is the 52-week high and low of Gujarat Kidney & Super Speciality Ltd.?
The 52-week high is ₹209.8 and the 52-week low is ₹98.36.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Gujarat Kidney & Super Speciality Ltd. | ₹163.31 | ₹1,289 cr | 81.3 | — | 11.1% | 14.7% | 0.12 | +36.1% |
| Indraprastha Medical Corporation Limited | ₹305.65 | ₹2,797 cr | 14.9 | — | 27.5% | 30% | 0.05 | -46.9% |
| KMC Speciality Hospitals (India) Limited | ₹148.39 | ₹2,422 cr | 43.4 | — | 24.9% | 25.1% | 0.4 | +7.8% |
| Shalby Ltd. | ₹120.64 | ₹1,306 cr | 32.8 | — | 3.7% | 6% | 0.59 | -51.3% |
| GPT Healthcare Limited | ₹132.68 | ₹1,089 cr | 23 | — | 16.3% | 16.2% | 0.34 | -11.6% |
| KRM Ayurveda Ltd. | ₹225.45 | ₹479 cr | — | — | — | — | — | +31.0% |
Compare GKSL with INDRAMEDCO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GKSL in NSE Scanner →